Differential Contributory Roles of Nucleotide Excision and Homologous Recombination Repair for Enhancing Cisplatin Sensitivity in Human Ovarian Cancer Cells

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2011 Mar 10

PMID 21385444

Citations 32

Authors

Qi-En Wang

Keisha Milum

Chunhua Han

Yi-Wen Huang

Gulzar Wani

Jurgen Thomale

Altaf A Wani

Affiliations

Soon will be listed here.

Abstract

Background: While platinum-based chemotherapeutic agents are widely used to treat various solid tumors, the acquired platinum resistance is a major impediment in their successful treatment. Since enhanced DNA repair capacity is a major factor in conferring cisplatin resistance, targeting of DNA repair pathways is an effective stratagem for overcoming cisplatin resistance. This study was designed to delineate the role of nucleotide excision repair (NER), the principal mechanism for the removal of cisplatin-induced DNA intrastrand crosslinks, in cisplatin resistance and reveal the impact of DNA repair interference on cisplatin sensitivity in human ovarian cancer cells.

Results: We assessed the inherent NER efficiency of multiple matched pairs of cisplatin-sensitive and -resistant ovarian cancer cell lines and their expression of NER-related factors at mRNA and protein levels. Our results showed that only the cisplatin-resistant ovarian cancer cell line PEO4 possessed an increased NER capacity compared to its inherently NER-inefficient parental line PEO1. Several other cisplatin-resistant cell lines, including CP70, CDDP and 2008C13, exhibited a normal and parental cell-comparable NER capacity for removing cisplatin-induced DNA intrastrand cross-links (Pt-GG). Concomitant gene expression analysis revealed discordance in mRNA and protein levels of NER factors in various ovarian cancer cell lines and NER proteins level were unrelated to the cisplatin sensitivity of these cell lines. Although knockdown of NER factors was able to compromise the NER efficiency, it only caused a minimal effect on cisplatin sensitivity. On the contrary, downregulation of BRCA2, a critical protein for homologous recombination repair (HRR), significantly enhanced the efficacy of cisplatin in killing ovarian cancer cell line PEO4.

Conclusion: Our studies indicate that the level of NER factors in ovarian cancer cell lines is neither a determinant of their NER capacity nor of the sensitivity to cisplatin, and suggest that manipulation of the HRR but not the NER factor expression provides an effective strategy for sensitizing cisplatin-resistant tumors to platinating agents.

Citing Articles

Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition.

Hassel J, Zimmer L, Sickmann T, Eigentler T, Meier F, Mohr P Cancers (Basel). 2023; 15(13).

PMID: 37444558 PMC: 10341224. DOI: 10.3390/cancers15133448.

p53-Dependent Cytoprotective Mechanisms behind Resistance to Chemo-Radiotherapeutic Agents Used in Cancer Treatment.

Krishnaraj J, Yamamoto T, Ohki R Cancers (Basel). 2023; 15(13).

PMID: 37444509 PMC: 10341282. DOI: 10.3390/cancers15133399.

LC-MS/MS Phytochemical Profiling, Antioxidant Activity, and Cytotoxicity of the Ethanolic Extract of L. against Breast Cancer Cell Lines: Computational Studies and Experimental Validation.

Elbouzidi A, Ouassou H, Aherkou M, Kharchoufa L, Meskali N, Baraich A Pharmaceuticals (Basel). 2022; 15(9).

PMID: 36145377 PMC: 9503641. DOI: 10.3390/ph15091156.

Nelfinavir Induces Cytotoxicity towards High-Grade Serous Ovarian Cancer Cells, Involving Induction of the Unfolded Protein Response, Modulation of Protein Synthesis, DNA Damage, Lysosomal Impairment, and Potentiation of Toxicity Caused by....

Subeha M, Goyeneche A, Bustamante P, Lisio M, Burnier J, Telleria C Cancers (Basel). 2022; 14(1).

PMID: 35008264 PMC: 8750028. DOI: 10.3390/cancers14010099.

The DNA damage inducible lncRNA SCAT7 regulates genomic integrity and topoisomerase 1 turnover in lung adenocarcinoma.

Statello L, Ali M, Reischl S, Mahale S, Thankaswamy Kosalai S, Huarte M NAR Cancer. 2021; 3(1):zcab002.

PMID: 34316698 PMC: 8209975. DOI: 10.1093/narcan/zcab002.

References

Ahmad A, Robinson A, Duensing A, van Drunen E, Beverloo H, Weisberg D . ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol. 2008; 28(16):5082-92. PMC: 2519706. DOI: 10.1128/MCB.00293-08. View

McHugh P, Spanswick V, Hartley J . Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol. 2002; 2(8):483-90. DOI: 10.1016/S1470-2045(01)00454-5. View

Barakat B, Wang Q, Han C, Milum K, Yin D, Zhao Q . Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosis. Int J Cancer. 2009; 127(4):977-88. PMC: 4180185. DOI: 10.1002/ijc.25112. View

Lehmann A, Stevens S . A rapid procedure for measurement of DNA repair in human fibroblasts and for complementation analysis of xeroderma pigmentosum cells. Mutat Res. 1980; 69(1):177-90. DOI: 10.1016/0027-5107(80)90187-6. View

Koberle B, Roginskaya V, Zima K, Masters J, Wood R . Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation. Mol Carcinog. 2008; 47(8):580-6. DOI: 10.1002/mc.20418. View

Olaussen K, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V . DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006; 355(10):983-91. DOI: 10.1056/NEJMoa060570. View

Johnson S, Swiggard P, Handel L, Brennan J, Godwin A, Ozols R . Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res. 1994; 54(22):5911-6. View

Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S . Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol. 2008; 26(1):20-5. DOI: 10.1200/JCO.2007.11.6905. View

Wu X, Fan W, Xu S, Zhou Y . Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells. Clin Cancer Res. 2003; 9(16 Pt 1):5874-9. View

10.

Johnson S, Perez R, Godwin A, Yeung A, Handel L, Ozols R . Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol. 1994; 47(4):689-97. DOI: 10.1016/0006-2952(94)90132-5. View

11.

Araujo S, Nigg E, Wood R . Strong functional interactions of TFIIH with XPC and XPG in human DNA nucleotide excision repair, without a preassembled repairosome. Mol Cell Biol. 2001; 21(7):2281-91. PMC: 86862. DOI: 10.1128/MCB.21.7.2281-2291.2001. View

12.

Ferry K, Hamilton T, Johnson S . Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol. 2000; 60(9):1305-13. DOI: 10.1016/s0006-2952(00)00441-x. View

13.

Sugasawa K, Ng J, Masutani C, Iwai S, van der Spek P, Eker A . Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. Mol Cell. 1998; 2(2):223-32. DOI: 10.1016/s1097-2765(00)80132-x. View

14.

Wang Q, Zhu Q, Wani G, El-Mahdy M, Li J, Wani A . DNA repair factor XPC is modified by SUMO-1 and ubiquitin following UV irradiation. Nucleic Acids Res. 2005; 33(13):4023-34. PMC: 1178000. DOI: 10.1093/nar/gki684. View

15.

Araujo S, Tirode F, Coin F, Pospiech H, Syvaoja J, Stucki M . Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK. Genes Dev. 2000; 14(3):349-59. PMC: 316364. View

16.

Petit C, Sancar A . Nucleotide excision repair: from E. coli to man. Biochimie. 1999; 81(1-2):15-25. DOI: 10.1016/s0300-9084(99)80034-0. View

17.

Volker M, Mone M, Karmakar P, van Hoffen A, Schul W, Vermeulen W . Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell. 2001; 8(1):213-24. DOI: 10.1016/s1097-2765(01)00281-7. View

18.

Muotri A, Marchetto M, Suzuki M, Okazaki K, Lotfi C, Brumatti G . Low amounts of the DNA repair XPA protein are sufficient to recover UV-resistance. Carcinogenesis. 2002; 23(6):1039-46. DOI: 10.1093/carcin/23.6.1039. View

19.

Cohen S, Lippard S . Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol. 2001; 67:93-130. DOI: 10.1016/s0079-6603(01)67026-0. View

20.

Koc A, Wheeler L, Mathews C, Merrill G . Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools. J Biol Chem. 2003; 279(1):223-30. DOI: 10.1074/jbc.M303952200. View